Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2001

View Archived Issues

Company Profile: m-phasys

Schering AG makes good start to 2001

Watson seeks FDA approval for overactive bladder treatment

Anika receives premarket approval from FDA for Staarvisc ophthalmic product

Paclitaxel-chlorambucil hybrid shows supraadditive activity in certain tumor models

MitoExtra and mitomycin C bioequivalent in phase I study

IY-81149 more potent than omeprazole in vitro and in vivo

Dibenzophenanthroline G-quadruplex ligands inhibit telomerase activity

New class of rilmenidine analogues with high selectivity for I1 receptors and hypotensive activity

Reviparin compared to heparin in deep vein thrombosis

Two new pseudomycin analogues with desirable antifungal and toxicity profiles

Novartis files for approval of Diovan for heart failure in several countries

Promising interim phase I results reported for Metabolic's obesity drug

Abaperidone advances to clinical testing based on favorable activity/side effect profile

Safety of two dose regimens of NXY-059 assessed in patients with stroke

Additional trial results reported for CAT's ocular agent CAT-152

NexMed's Femprox safe and well tolerated in phase I trials

In vivo antitumor and apoptosis-inducing activity described for new proteasome inhibitor

Phase II trial evaluates combination of peptide and standard chemotherapy for ovarian cancer

M. catarrhalis peptides useful for preparing UTI vaccines

Synthesis, activity and use reported by Byk Gulden for new tryptase inhibitors

Baylor U. designs new cytotoxic tubulin polymerization inhibitors

Patent issued to Abbott for new agents for controlling neurotransmitter release

Nitrile cathepsin S inhibitors in the AxyS pipeline

Research at BASF leads to identification of inhibitors of angiogenic kinases

Panacos receives SBIR grant from NIH for development of HIV drug